



Theratechnologies Announces New Positive Results For Two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

April 27, 2020

TH1902 and TH1904 more effective and safer in vivo compared to current standard ovarian cancer treatments

New data presented during the AACR Virtual Annual Meeting

Montreal, Canada – April 27, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that new positive results about its two investigational peptide-drug conjugates (PDC) TH1902 and TH1904 will be presented tomorrow during an oral presentation at a virtual session of the Annual Meeting of the American Association for Cancer Research (AACR).